{"title":"肺移植受者对第三和第四剂 SARS-CoV-2 mRNA 疫苗的体液反应增强。","authors":"Shinichi Kawana , Seiichiro Sugimoto , Kei Matsubara , Haruki Choshi , Shin Tanaka , Megumi Ishihara , Tomohiro Habu , Kohei Hashimoto , Ken Suzawa , Kazuhiko Shien , Kentaroh Miyoshi , Mikio Okazaki , Masanori Nakayama , Shinichi Toyooka","doi":"10.1016/j.resinv.2024.07.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Since lung transplant recipients (LTRs) exhibit low immunogenicity after two doses of SARS-CoV-2 mRNA vaccines, optimal vaccine strategies for SARS-CoV-2 are required in LTRs. This study aimed to investigate the efficacy and safety of the third and fourth doses of the SARS-CoV-2 mRNA vaccines in LTRs.</p></div><div><h3>Methods</h3><p>We conducted a single-center study of 73 LTRs and 23 healthy controls (HCs). Participants received two-to-four doses of SARS-CoV-2 mRNA vaccines. The LTRs were divided into three groups based on the number of vaccine dose. IgG titers against SARS-CoV-2 spike protein were measured, and adverse events were assessed. Factors associated with humoral response were analyzed using univariate and multivariate analyses.</p></div><div><h3>Results</h3><p>The Dose 4 group (n = 27) had a higher humoral response rate (<em>P</em> = 0.018) and higher levels of anti-SARS-CoV-2 IgG antibody (<em>P</em> = 0.04) than the Dose 2 group (n = 14). The Dose 3 group (n = 32) had lower humoral response rates (<em>P</em> = 0.005) and levels of anti-SARS-CoV-2 IgG antibody (<em>P</em> = 0.0005) than the HCs (n = 23) even after the same dose. Systemic adverse events were milder in the LTRs than in the HCs (<em>P</em> < 0.05). Increased number of vaccine dose was identified as a predictor of positive humoral response (<em>P</em> = 0.021).</p></div><div><h3>Conclusion</h3><p>Booster doses of SARS-CoV-2 mRNA vaccines may enhance humoral response with mild adverse events in LTRs. Repeated vaccination might be warranted for LTRs to prevent SARS-CoV-2 infection.</p></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"62 5","pages":"Pages 804-810"},"PeriodicalIF":2.4000,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Augmented humoral response to third and fourth dose of SARS-CoV-2 mRNA vaccines in lung transplant recipients\",\"authors\":\"Shinichi Kawana , Seiichiro Sugimoto , Kei Matsubara , Haruki Choshi , Shin Tanaka , Megumi Ishihara , Tomohiro Habu , Kohei Hashimoto , Ken Suzawa , Kazuhiko Shien , Kentaroh Miyoshi , Mikio Okazaki , Masanori Nakayama , Shinichi Toyooka\",\"doi\":\"10.1016/j.resinv.2024.07.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Since lung transplant recipients (LTRs) exhibit low immunogenicity after two doses of SARS-CoV-2 mRNA vaccines, optimal vaccine strategies for SARS-CoV-2 are required in LTRs. This study aimed to investigate the efficacy and safety of the third and fourth doses of the SARS-CoV-2 mRNA vaccines in LTRs.</p></div><div><h3>Methods</h3><p>We conducted a single-center study of 73 LTRs and 23 healthy controls (HCs). Participants received two-to-four doses of SARS-CoV-2 mRNA vaccines. The LTRs were divided into three groups based on the number of vaccine dose. IgG titers against SARS-CoV-2 spike protein were measured, and adverse events were assessed. Factors associated with humoral response were analyzed using univariate and multivariate analyses.</p></div><div><h3>Results</h3><p>The Dose 4 group (n = 27) had a higher humoral response rate (<em>P</em> = 0.018) and higher levels of anti-SARS-CoV-2 IgG antibody (<em>P</em> = 0.04) than the Dose 2 group (n = 14). The Dose 3 group (n = 32) had lower humoral response rates (<em>P</em> = 0.005) and levels of anti-SARS-CoV-2 IgG antibody (<em>P</em> = 0.0005) than the HCs (n = 23) even after the same dose. Systemic adverse events were milder in the LTRs than in the HCs (<em>P</em> < 0.05). Increased number of vaccine dose was identified as a predictor of positive humoral response (<em>P</em> = 0.021).</p></div><div><h3>Conclusion</h3><p>Booster doses of SARS-CoV-2 mRNA vaccines may enhance humoral response with mild adverse events in LTRs. Repeated vaccination might be warranted for LTRs to prevent SARS-CoV-2 infection.</p></div>\",\"PeriodicalId\":20934,\"journal\":{\"name\":\"Respiratory investigation\",\"volume\":\"62 5\",\"pages\":\"Pages 804-810\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-07-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Respiratory investigation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2212534524001059\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory investigation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212534524001059","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
Augmented humoral response to third and fourth dose of SARS-CoV-2 mRNA vaccines in lung transplant recipients
Background
Since lung transplant recipients (LTRs) exhibit low immunogenicity after two doses of SARS-CoV-2 mRNA vaccines, optimal vaccine strategies for SARS-CoV-2 are required in LTRs. This study aimed to investigate the efficacy and safety of the third and fourth doses of the SARS-CoV-2 mRNA vaccines in LTRs.
Methods
We conducted a single-center study of 73 LTRs and 23 healthy controls (HCs). Participants received two-to-four doses of SARS-CoV-2 mRNA vaccines. The LTRs were divided into three groups based on the number of vaccine dose. IgG titers against SARS-CoV-2 spike protein were measured, and adverse events were assessed. Factors associated with humoral response were analyzed using univariate and multivariate analyses.
Results
The Dose 4 group (n = 27) had a higher humoral response rate (P = 0.018) and higher levels of anti-SARS-CoV-2 IgG antibody (P = 0.04) than the Dose 2 group (n = 14). The Dose 3 group (n = 32) had lower humoral response rates (P = 0.005) and levels of anti-SARS-CoV-2 IgG antibody (P = 0.0005) than the HCs (n = 23) even after the same dose. Systemic adverse events were milder in the LTRs than in the HCs (P < 0.05). Increased number of vaccine dose was identified as a predictor of positive humoral response (P = 0.021).
Conclusion
Booster doses of SARS-CoV-2 mRNA vaccines may enhance humoral response with mild adverse events in LTRs. Repeated vaccination might be warranted for LTRs to prevent SARS-CoV-2 infection.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
